Pharmaceutical

The pharmaceutical industry in India is a vital sector that significantly contributes to both the national economy and global healthcare. Renowned for its cost-effective manufacturing and substantial production capabilities, India is a leading provider of generic drugs, supplying over 20% of the global market. The industry is valued at around USD 42 billion as of 2023, with projections indicating it will grow to USD 65 billion by 2024.

The Pharmaceutical Industry Does Not Cure, It Creates Customers 

The industry added almost 1.32% to the Gross Value Added in the Indian Economy for the year 2020-21. The Pharmaceuticals sector had a total annual revenue of $42.34 billion in fiscal year 2021-22. Primary sectors of the Indian Pharmaceutical Industry comprise generic drugs, over-the-counter medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics.

The Vision Pharma 2047: By the year 2047, the Government aims to accomplish the following goals: 

• Make India a global leader in the manufacturing of affordable, innovative & quality pharmaceuticals & medical devices for the goal of Vasudhaiva kutumbakam
• Vishwaguru in innovation & Research for delivering healthcare products to future generations in a sustainable manner, Introduction of natural products.
• Ensure accessibility & affordability of patient-centric products for better healthcare outcomes for universal health coverage by building upon partnerships across industry, science, and government
• Contribute to the Health Systems to attain a union of equity, efficacy, and efficiency toward developing a holistic product profile focusing on NCDs, AMR, and rare & neglected diseases.
• Create Equilibrium between social, economic & governance aspects through facilitative, balanced & progressive policy and regulatory framework
• Reduce India’s Carbon footprint in Pharma-Med Tech to align with the Hon’ble PM’s vision for Panchamrita
• Identifying critical suppliers, de-risking & decarbonizing the supply chain, and promoting local sourcing
• Medical devices are essential components of worldwide supply chains, including raw materials, components, spare parts, assemblies, and subassemblies.
• Digitalization and technology upgradation in the delivery of services & products under Jan Aushadhi Pariyojana

India's government is taking a multifaceted approach, engaging industry and academia, developing infrastructure, and more to boost research and innovation in the pharmaceutical sector. The policies mentioned above are helping to create an environment that is conducive to innovation in the pharmaceutical sector.

India's pharmaceutical industry is in a prime position to maintain its leading role in research and innovation in the future. The nation's robust scientific and technological foundation, increasing government backing, and expansive local market will continue to fuel innovation. In addition, India’s cost-competitive manufacturing capabilities will make it an attractive location for global pharmaceutical companies to conduct R&D

The pharmaceutical industry in India is a significant sector, contributing to both the domestic economy and the global healthcare market. Known for its robust production capabilities and cost-effective manufacturing, the Indian pharmaceutical industry holds a prominent position globally

• As of 2023, the Indian pharmaceutical market is valued at around USD 42 billion and is projected to grow to USD 65 billion by 2024.
• The industry is experiencing a CAGR (Compound Annual Growth Rate) of about 10-12%.

Global Standing

• India is the largest provider of generic drugs globally, supplying over 20% of the global generic drug market.
• The country is also a major supplier of vaccines, accounting for over 50% of global vaccine demand.

Active Pharmaceutical Ingredients (APIs):

• India is one of the leading producers of APIs, supplying to both domestic and international markets.
• Efforts are being made to reduce dependency on imports, particularly from China, through government initiatives like the Production Linked Incentive (PLI) Scheme.

Formulations:

• The formulations segment involves the production of finished dosage forms like tablets, capsules, and injectables.
• Indian companies are known for their high-quality generic formulations, which are exported to over 200 countries.

Biotechnology:

• The biotech sector in India is growing rapidly, focusing on biopharmaceuticals, biosimilars, and bio-services.
• India is home to several leading biotech companies that are making significant advancements in drug discovery and development.

Contract Research and Manufacturing Services (CRAMS):

• India has emerged as a preferred destination for CRAMS due to its skilled workforce, cost advantages, and strong regulatory framework.
• The country offers a range of services including clinical trials, contract manufacturing, and drug development.

Central Drugs Standard Control Organization (CDSCO):

• CDSCO, under the Ministry of Health and Family Welfare, is the primary regulatory body responsible for drug approval and quality control.
• The Drug Controller General of India (DCGI) oversees the implementation of various regulations.

Good Manufacturing Practices (GMP):

• Indian pharmaceutical companies adhere to GMP guidelines, ensuring high standards of production and quality control.

Regulatory Compliance:

• Maintaining compliance with both domestic and international regulations is a significant challenge.
• Regular audits and stringent quality checks are necessary to meet global standards.

Quality Control:

• Ensuring consistent quality in manufacturing processes is critical to maintaining the reputation of Indian pharmaceuticals.

Supply Chain Disruptions:

• The industry faces challenges related to raw material shortages and supply chain disruptions, particularly highlighted during the COVID-19 pandemic.

Production Linked Incentive (PLI) Scheme:

Aimed at boosting domestic manufacturing and reducing import dependency, the PLI scheme offers financial incentives for production and R&D.

Atmanirbhar Bharat:

The self-reliant India initiative encourages local production of APIs and intermediates to strengthen the domestic pharmaceutical industry.

Innovation and R&D:

Increased investment in R&D is expected to drive innovation, with a focus on new drug development, biosimilars, and biotechnology.

Market Expansion:

Indian pharmaceutical companies are exploring new markets and expanding their global footprint, particularly in emerging economies.

Digital Transformation:

Adoption of digital technologies, such as AI and big data analytics, is set to revolutionize drug discovery, manufacturing, and distribution processes.

The Indian pharmaceutical industry is poised for significant growth, driven by its cost-effective manufacturing, robust R&D capabilities, and supportive government policies. As it continues to evolve, the industry is expected to play an increasingly indispensable role in global healthcare.

Corpseed’s comprehensive services help pharmaceutical companies navigate the complex regulatory landscape, achieve compliance, and capitalize on growth opportunities. By offering expert guidance and support, Corpseed ensures that pharmaceutical businesses can focus on innovation and delivering quality healthcare products to the market.